AstraZeneca PLC (AZN)

AZN (NYSE:Drugs)
$74.94
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | AZN Avg Daily Volume: 5,509,400
Last Update: 07/23/14 - 4:01 PM EDT
Volume: 0
YTD Performance: 26.23%
Open: $0.00
Previous Close: $74.94
52 Week Range: $48.54 - $82.68
Oustanding Shares: 1,262,563,639
Market Cap: 94,086,242,378
6-Month Chart
TheStreet Ratings Grade for AZN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 1 1 2 2
Moderate Buy 0 0 0 0
Hold 4 5 3 3
Moderate Sell 0 0 0 1
Strong Sell 1 1 1 1
Mean Rec. 3.00 3.00 2.67 2.86
Latest Dividend: 1.90
Latest Dividend Yield: 3.73%
Dividend Ex-Date: 02/19/14
Price Earnings Ratio: 36.84
Price Earnings Comparisons:
AZN Sector Avg. S&P 500
36.84 45.70 28.87
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
10.56% 47.35% 50.88%
GROWTH 12 Mo 3 Yr CAGR
Revenue -8.10 -0.23 -0.08
Net Income -59.40 -0.68 -0.31
EPS -59.10 -0.64 -0.28
Earnings for AZN:
EBITDA 7.70B
Revenue 25.71B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (12/14) FY (12/15)
Average Estimate $1.13 $1.00 $4.36 $4.25
Number of Analysts 1 1 6 6
High Estimate $1.13 $1.00 $4.60 $4.40
Low Estimate $1.13 $1.00 $4.24 $4.12
Prior Year $1.20 $1.21 $5.05 $4.36
Growth Rate (Year over Year) -5.83% -17.36% -13.63% -2.56%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Each of these 'real' American firms is now a buyout candidate because of the ridiculous U.S. tax code.
You're looking at one.
Bullish
May 21, 2014 | 8:17 AM EDT
AZN raised its numbers, according to Barclays. Driven by contribution from pipeline products to push sakes growth. $40 price target and...
Across all sectors, stocks are rising in tandem with rates -- but I think this stupidity will end soon.

AstraZeneca Zigs and Zags Real Money Pro($)

The shares have more moves than a shortstop batting .110.
I sold out of my AstraZenca long for a nice gain.

The Early Bird Gets the Worm Real Money Pro($)

Just collected some profits on my premarket AstraZeneca purchase.

Morning Market Look Real Money Pro($)

Maybe the rally has simply been too soon and too fast.
The biggest overvaluation is the undervaluation of risk in that market.

Columnist Conversations

Lang:
After two weeks off we are BACK in gear with a fresh new webinar, after the close today. Sign up below, alway...
Lang:
Amazing growth metrics for FB last night has this one perking toward a new all time high this am. Back on Jun...
To go along with my column this morning how there is no giddiness in the market, this week's AAII bulls are th...
The semiconductor sector performed poorly today with the Market Vectors Semiconductor (SMH) fund down over 2% ...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.